CO6862151A2 - 4-(8-metoxi-1-((1-metoxipropan-2-il)-2-(tetrahidro-2h-piran-4-il)-1 h-imidazol[4,5-c]quinolin-7-il)-3,5-dimetilisoxazol y su uso como inhibidor de bromodominio - Google Patents

4-(8-metoxi-1-((1-metoxipropan-2-il)-2-(tetrahidro-2h-piran-4-il)-1 h-imidazol[4,5-c]quinolin-7-il)-3,5-dimetilisoxazol y su uso como inhibidor de bromodominio

Info

Publication number
CO6862151A2
CO6862151A2 CO14011125A CO14011125A CO6862151A2 CO 6862151 A2 CO6862151 A2 CO 6862151A2 CO 14011125 A CO14011125 A CO 14011125A CO 14011125 A CO14011125 A CO 14011125A CO 6862151 A2 CO6862151 A2 CO 6862151A2
Authority
CO
Colombia
Prior art keywords
dimethylisoxazole
methoxypropan
quinolin
imidazol
pyran
Prior art date
Application number
CO14011125A
Other languages
English (en)
Spanish (es)
Inventor
Emmanuel Hubert Demont
Katherine Louise Jones
Robert J Watson
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of CO6862151A2 publication Critical patent/CO6862151A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CO14011125A 2011-08-17 2014-01-21 4-(8-metoxi-1-((1-metoxipropan-2-il)-2-(tetrahidro-2h-piran-4-il)-1 h-imidazol[4,5-c]quinolin-7-il)-3,5-dimetilisoxazol y su uso como inhibidor de bromodominio CO6862151A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1114103.3A GB201114103D0 (en) 2011-08-17 2011-08-17 Novel compounds

Publications (1)

Publication Number Publication Date
CO6862151A2 true CO6862151A2 (es) 2014-02-10

Family

ID=44764570

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14011125A CO6862151A2 (es) 2011-08-17 2014-01-21 4-(8-metoxi-1-((1-metoxipropan-2-il)-2-(tetrahidro-2h-piran-4-il)-1 h-imidazol[4,5-c]quinolin-7-il)-3,5-dimetilisoxazol y su uso como inhibidor de bromodominio

Country Status (38)

Country Link
US (4) US9067936B2 (enEXAMPLES)
EP (2) EP2744809B1 (enEXAMPLES)
JP (1) JP6059723B2 (enEXAMPLES)
KR (1) KR20140064878A (enEXAMPLES)
CN (1) CN103889984B (enEXAMPLES)
AR (1) AR087545A1 (enEXAMPLES)
AU (1) AU2012296914B2 (enEXAMPLES)
BR (1) BR112014003681A8 (enEXAMPLES)
CA (1) CA2843537A1 (enEXAMPLES)
CL (1) CL2014000365A1 (enEXAMPLES)
CO (1) CO6862151A2 (enEXAMPLES)
CR (1) CR20140076A (enEXAMPLES)
CY (1) CY1118370T1 (enEXAMPLES)
DK (1) DK2744809T3 (enEXAMPLES)
DO (1) DOP2014000031A (enEXAMPLES)
EA (1) EA023374B1 (enEXAMPLES)
ES (1) ES2609857T3 (enEXAMPLES)
GB (1) GB201114103D0 (enEXAMPLES)
HR (1) HRP20161674T1 (enEXAMPLES)
HU (1) HUE030106T2 (enEXAMPLES)
IL (1) IL230489A (enEXAMPLES)
IN (1) IN2014CN00568A (enEXAMPLES)
JO (1) JO3187B1 (enEXAMPLES)
LT (1) LT2744809T (enEXAMPLES)
ME (1) ME02589B (enEXAMPLES)
MX (1) MX350597B (enEXAMPLES)
MY (1) MY170729A (enEXAMPLES)
PE (1) PE20141406A1 (enEXAMPLES)
PH (1) PH12014500379A1 (enEXAMPLES)
PL (1) PL2744809T3 (enEXAMPLES)
PT (1) PT2744809T (enEXAMPLES)
RS (1) RS55560B1 (enEXAMPLES)
SI (1) SI2744809T1 (enEXAMPLES)
SM (2) SMT201700005T1 (enEXAMPLES)
TW (1) TWI558704B (enEXAMPLES)
UA (1) UA110838C2 (enEXAMPLES)
UY (1) UY34264A (enEXAMPLES)
WO (1) WO2013024104A1 (enEXAMPLES)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
US9249161B2 (en) 2010-12-02 2016-02-02 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2012151512A2 (en) 2011-05-04 2012-11-08 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2012174487A2 (en) 2011-06-17 2012-12-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
GB201114103D0 (en) * 2011-08-17 2011-09-28 Glaxosmithkline Llc Novel compounds
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
EP2864336B1 (en) 2012-06-06 2016-11-23 Constellation Pharmaceuticals, Inc. Benzo[b]isoxazoloazepine bromodomain inhibitors and uses thereof
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
US9271978B2 (en) 2012-12-21 2016-03-01 Zenith Epigenetics Corp. Heterocyclic compounds as bromodomain inhibitors
MX2015012005A (es) * 2013-03-11 2016-04-04 Abbvie Inc Inhibidores de bromodominio.
JP2016516701A (ja) 2013-03-11 2016-06-09 アッヴィ・インコーポレイテッド 縮合四環系ブロモドメイン阻害剤
AU2014249192B2 (en) 2013-03-11 2017-12-21 The Regents Of The University Of Michigan BET bromodomain inhibitors and therapeutic methods using the same
UA119848C2 (uk) 2013-03-15 2019-08-27 Інсайт Холдинґс Корпорейшн Трициклічні гетероцикли як інгібітори білків бет
TWI530499B (zh) * 2013-03-28 2016-04-21 吉李德科學股份有限公司 作為溴結構域（ｂｒｏｍｏｄｏｍａｉｎ）抑制劑之苯並咪唑酮衍生物類
BR112015031073B1 (pt) 2013-06-21 2022-11-29 Zenith Epigenetics Ltd Compostos inibidores bicíclicos de bromodomínio e composição farmacêutica contendo os referidos compostos
CN105473581B (zh) 2013-06-21 2019-04-23 齐尼思表观遗传学有限公司 作为溴结构域抑制剂的新取代的双环化合物
WO2015006193A1 (en) 2013-07-08 2015-01-15 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
US9855271B2 (en) 2013-07-31 2018-01-02 Zenith Epigenetics Ltd. Quinazolinones as bromodomain inhibitors
WO2015049629A1 (en) * 2013-10-01 2015-04-09 Piramal Enterprises Limited Imidazoquinoline compounds as bromodomain inhibitors
WO2015081189A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
CN107074861A (zh) 2014-02-28 2017-08-18 密执安大学评议会 作为bet溴结构域抑制剂的9h嘧啶并[4，5‑b]吲哚和相关类似物
ME03763B (me) 2014-04-23 2021-04-20 Incyte Corp 1h-pirrolo[2,3-c]piridin-7(6h)-oni i pirazolo[3,4-c]piridin-7(6h)-oni kao inhibitori bet proteina
SI3157928T1 (sl) 2014-06-20 2019-06-28 Constellation Pharmaceuticals, Inc. Kristalinične oblike 2-((4S)-6-(4-klorofenil)-1-metil-4H-benzo(C)izoksazolo(4,5-E)azepin-4-il acetamida
ES2855225T3 (es) 2014-09-15 2021-09-23 Incyte Corp Heterociclos tricíclicos para su uso como inhibidores de proteínas BET
CA2966303A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
HK1245246A1 (zh) 2014-12-01 2018-08-24 恒翼生物医药科技(上海)有限公司 作为溴域抑制剂的取代吡啶酮
JP2017537946A (ja) 2014-12-11 2017-12-21 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． ブロモドメイン阻害剤としての置換複素環
EP3233846A4 (en) 2014-12-17 2018-07-18 Zenith Epigenetics Ltd. Inhibitors of bromodomains
US10259809B2 (en) 2015-02-03 2019-04-16 Trillium Therapeutics Inc. Fluorinated imidazo[4,5-C]quinoline derivatives as inhibitors of bromodomain containing proteins
US10307407B2 (en) 2015-02-27 2019-06-04 The Regents Of The University Of Michigan 9H-pyrimido [4,5-B] indoles as BET bromodomain inhibitors
GB201504689D0 (en) * 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201504694D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
WO2016186453A1 (en) * 2015-05-20 2016-11-24 Kainos Medicine, Inc. Quinoline derivatives as bromodomain inhibitors
WO2016196065A1 (en) 2015-05-29 2016-12-08 Genentech, Inc. Methods and compositions for assessing responsiveness of cancers to bet inhibitors
WO2016199943A1 (en) * 2015-06-11 2016-12-15 Takeda Pharmaceutical Company Limited Heterocyclic compounds
AU2016305513A1 (en) 2015-08-11 2018-03-08 Neomed Institute Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticals
US10836742B2 (en) 2015-08-11 2020-11-17 Neomed Institute N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
KR102784592B1 (ko) 2015-08-12 2025-03-19 에피제네틱스, 인크. 치환된 벤즈이미다졸, 그의 제조법 및 제약으로서의 그의 용도
US10501459B2 (en) 2015-10-21 2019-12-10 Neomed Institute Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors
US20170121347A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
WO2017127930A1 (en) 2016-01-28 2017-08-03 Neomed Institute Substituted [1,2,4]triazolo[4,3-a]pyridines, their preparation and their use as pharmaceuticals
US11548899B2 (en) 2016-02-15 2023-01-10 The Regents Of The University Of Michigan Fused 1,4-oxazepines and related analogs as BET bromodomain inhibitors
EP3440082A1 (en) 2016-04-06 2019-02-13 The Regents of The University of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
MX2018012174A (es) 2016-04-06 2019-07-08 Univ Michigan Regents Degradantes de proteina homologa de proteina murina de cromosoma diminuto doble (mdm2).
UA123168C2 (uk) 2016-04-12 2021-02-24 Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган Деструктори білка вет
CA3028689A1 (en) 2016-06-20 2017-12-28 Incyte Corporation Crystalline solid forms of a bet inhibitor
JP7035027B2 (ja) 2016-09-13 2022-03-14 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン Ｂｅｔタンパク質分解物質としての縮合１，４－ジアゼピン
CN110062759B (zh) 2016-09-13 2022-05-24 密执安大学评议会 作为bet蛋白降解剂的稠合的1,4-氧氮杂䓬
WO2018144789A1 (en) 2017-02-03 2018-08-09 The Regents Of The University Of Michigan Fused 1,4-diazepines as bet bromodomain inhibitors
US11267822B2 (en) 2017-09-13 2022-03-08 The Regents Of The University Of Michigan BET bromodomain protein degraders with cleavable linkers
CN108033957A (zh) * 2018-01-09 2018-05-15 中国药科大学 一种喹啉类BET bromodomain抑制剂及其制备方法和用途
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2022132049A1 (en) * 2020-12-17 2022-06-23 National University Of Singapore Treating cancers using bet inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
US7091214B2 (en) 2002-12-20 2006-08-15 3M Innovative Properties Co. Aryl substituted Imidazoquinolines
CN1901958B (zh) 2003-11-03 2011-03-09 葛兰素集团有限公司 流体分配装置
CA2546117A1 (en) 2003-11-21 2005-06-16 Novartis Ag 1h-imidazoquinoline derivatives as protein kinase inhibitors
US8658666B2 (en) 2005-02-11 2014-02-25 3M Innovative Properties Company Substituted imidazoquinolines and imidazonaphthyridines
CA2623541A1 (en) 2005-09-23 2007-03-29 Coley Pharmaceutical Group, Inc. Method for 1h-imidazo[4,5-c]pyridines and analogs thereof
KR20080077982A (ko) 2005-12-16 2008-08-26 콜레이 파마시티컬 그룹, 인코포레이티드 치환된 이미다조퀴놀린, 이미다조나프티리딘 및이미다조피리딘, 조성물 및 방법
JP2008156311A (ja) 2006-12-26 2008-07-10 Institute Of Physical & Chemical Research Ｂｒｄ２ブロモドメイン結合剤
CN101910182B (zh) * 2007-12-28 2013-07-17 田边三菱制药株式会社 抗癌剂
GB0919434D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919423D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
ME02356B (me) * 2009-11-05 2016-06-20 Glaxosmithkline Llc Inhibitor bromodomena benzodiazepina
GB0919432D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
GB201106799D0 (en) 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
GB201114103D0 (en) 2011-08-17 2011-09-28 Glaxosmithkline Llc Novel compounds

Also Published As

Publication number Publication date
ME02589B (me) 2017-06-20
MX350597B (es) 2017-09-11
CN103889984B (zh) 2016-01-13
PH12014500379A1 (en) 2021-07-12
NZ620263A (en) 2016-04-29
MY170729A (en) 2019-08-27
US9610284B2 (en) 2017-04-04
EA201490200A1 (ru) 2014-07-30
CA2843537A1 (en) 2013-02-21
CY1118370T1 (el) 2017-06-28
PE20141406A1 (es) 2014-10-25
LT2744809T (lt) 2016-12-27
SI2744809T1 (sl) 2017-01-31
RS55560B1 (sr) 2017-05-31
UY34264A (es) 2013-04-05
GB201114103D0 (en) 2011-09-28
BR112014003681A2 (pt) 2017-03-01
PT2744809T (pt) 2017-01-06
IL230489A0 (en) 2014-03-31
EA023374B1 (ru) 2016-05-31
AU2012296914A1 (en) 2014-02-13
HRP20161674T1 (hr) 2017-01-27
IN2014CN00568A (enEXAMPLES) 2015-04-03
DK2744809T3 (en) 2017-01-23
US9416130B2 (en) 2016-08-16
AU2012296914B2 (en) 2016-03-03
AR087545A1 (es) 2014-04-03
JP6059723B2 (ja) 2017-01-11
DOP2014000031A (es) 2014-06-01
US20150315184A1 (en) 2015-11-05
SMT201700005T1 (it) 2017-03-08
US20140171462A1 (en) 2014-06-19
BR112014003681A8 (pt) 2018-01-23
EP3150601A1 (en) 2017-04-05
US20160317529A1 (en) 2016-11-03
JO3187B1 (ar) 2018-03-08
UA110838C2 (uk) 2016-02-25
EP2744809A1 (en) 2014-06-25
TWI558704B (zh) 2016-11-21
TW201323424A (zh) 2013-06-16
CR20140076A (es) 2014-03-19
WO2013024104A1 (en) 2013-02-21
ES2609857T3 (es) 2017-04-24
HUE030106T2 (en) 2017-04-28
PL2744809T3 (pl) 2017-08-31
US20170157113A1 (en) 2017-06-08
US9067936B2 (en) 2015-06-30
IL230489A (en) 2016-07-31
KR20140064878A (ko) 2014-05-28
CL2014000365A1 (es) 2014-07-11
JP2014521735A (ja) 2014-08-28
US9861627B2 (en) 2018-01-09
EP2744809B1 (en) 2016-10-12
SMT201700005B (it) 2017-03-08
MX2014001834A (es) 2014-02-27
CN103889984A (zh) 2014-06-25

Similar Documents

Publication Publication Date Title
CO6862151A2 (es) 4-(8-metoxi-1-((1-metoxipropan-2-il)-2-(tetrahidro-2h-piran-4-il)-1 h-imidazol[4,5-c]quinolin-7-il)-3,5-dimetilisoxazol y su uso como inhibidor de bromodominio
SMT201600226B (it) Alcune amminopirimidine, loro composizioni e metodi per il loro uso
BR112012003445A2 (pt) aparelho dental sem o uso das maos para limpeza dos dentes
BR112013023681A2 (pt) compostos de álcool propargílico 6,5-heterocíclico e uso dos mesmos
BR112012022879A2 (pt) composto, composição farmacêutica, uso do composto e método de tratamento
BR112012031232A2 (pt) método, dispositivo e uso
BR112014014547A2 (pt) compostos antagonistas de e-selectina, composições e métodos de uso
PT2585437E (pt) Compostos de tioacetato, composições e métodos de uso
BRPI0907453A2 (pt) Compostos, uso e preparação dos mesmos
BR112014001255A2 (pt) composto, uso de um composto, combinação, e, composição farmacêutica
BRPI0817681A2 (pt) Compostos de tienopirimidina e pirazolopirimidina e seu uso como inibidores de mtor quinase e pi3 quinase
BR112013008259A2 (pt) composto, composição farmacêutica, e, uso de um composto
BR112013010988A2 (pt) composição fluída e uso
BR112013015397A2 (pt) composto, composição farmacêutica, e, uso de um composto
BR112012005736A2 (pt) di-hidro benzocicloalquiloximetil oxazolapirimidinonas substituídas, preparação e uso das mesmas
BR112013006016A2 (pt) compostos de azabenzotiazol, composições e métodos de uso
BR112014010739A2 (pt) agentes terapêuticos e uso dos mesmos
BR112013030302A2 (pt) composto, composição farmacêutica, uso de um composto, combinação de um composto e dispositivo
IT1403847B1 (it) Composizioni farmaceutiche comprendenti rifaximina e loro uso.
BRPI1012097A2 (pt) antagonistas e antagonistas inversos de histamina h3 e métodos de uso dos mesmos.
BR112014029642A2 (pt) composto, combinação de um composto, composição farmacêutica, uso de um composto, dispositivo e kit
BRPI1006996A2 (pt) composição, método e uso
BR112014005406A2 (pt) composição de vacina e respectivo uso
BR112013012175A2 (pt) combinação, coadministração, uso e método
BR112014000773A2 (pt) composições de nicotinamida e uso terapêutico das mesmas

Legal Events

Date Code Title Description
FC Application refused